Selank: Side Effects & Safety

Selank has a well-documented safety profile from its clinical trials and regulatory approval in Russia. It was classified as a low-toxicity compound with a high therapeutic index. The safety profile is particularly favorable when compared to benzodiazepine anxiolytics.

• Nasal irritation: Mild, transient discomfort with intranasal administration — the most commonly reported effect
• Injection site reactions: Minor redness at subcutaneous injection sites
• No sedation: Selank does not impair alertness or psychomotor function
• No dependence: No signs of tolerance, physical dependence, or withdrawal in clinical studies
• No cognitive impairment: Selank enhances rather than impairs cognitive function

Toxicological assessments found no mutagenic, teratogenic, or allergenic effects.

• Pregnancy and breastfeeding (insufficient safety data)
• Known hypersensitivity to tuftsin-derived peptides
• Active autoimmune conditions (due to immunomodulatory effects — could theoretically stimulate immune activity)

For the complete Selank overview, see the Selank complete guide. For a comparison with the related neuropeptide, see the Semax guide.